Genetic loci as cognition drug targets

Large GWAS that identify genes and pathways associated with intelligence provide concrete molecular hypotheses that pharmaceutical and biotech firms can follow up as potential cognitive‑enhancement or cognition‑restorative drug targets. The scientific finding is not only statistical association but points to biology (neural development, synaptic function) that is actionable for translational research. — If pursued, this will shift the public debate from abstract hereditarianism to concrete questions about R&D priorities, equity of access to cognitive enhancement, clinical safety, and regulatory oversight of neuro‑enhancement drugs.